Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cellegy Pharmaceuticals (CLGY) -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (221)	12/16/1999 11:55:00 AM
From: Howard Hoffman	Read Replies (2) \| Respond to of 322

Not peculiar at all. The value of Anogesic as a surgery-avoiding pharmaceutical is immense. It would be required, regardless of the price, by every medical insurance company, prior to surgery. The value of Anogesic for pain relief is better than say a pain in the ass, which is what CLGY has been to own recently. So, while this is ok news, it is not great news. Better to get Anogesic recognized as having some medicinal value, but the value will be nowhere near what it would have been. We still need answers from the company as to what went wrong on the first Phase 3.